spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ICON Establishes University Scholarship Programme to Provide Increased Opportunities for Underrepresented Groups to Study STEM-Related Courses

ICON plc

Thirty-three third level students across Ireland and the US to be supported over the next four years


Dublin, Ireland – 22 June 2022 – ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announces that it has established a scholarship programme to provide students from underrepresented groups increased opportunities to access third level education.


Through the programme, ICON is partnering with three universities in Ireland – Dublin City University (DCU), Trinity College Dublin (TCD) and the University of Limerick (UL) – as well as with the Thurgood Marshall College Fund (TMCF) in the US, to fund 33 scholarships for students of STEM (Science, Technology, Engineering & Mathematics) courses. TMCF is a not-for-profit organisation that supports nearly 300,000 students attending its 47 member-schools that include publicly-supported Historically Black Colleges and Universities (HBCUs).

ICON CEO, Dr. Steve Cutler, said: “In addition to inspiring more students to choose STEM-related university courses, we want to help students who, due to socio-economic or other circumstances, might not be able to benefit from third level education opportunities. We also want to contribute to building a diverse graduate pool of talented and ambitious STEM professionals who can help to ensure the future success of the life sciences industry.”

“Our partnership with ICON advances our overall mission to remove financial barriers for students,” said Dr. Eric Hart, Chief Programs Officer at Thurgood Marshall College Fund. "ICON's STEM scholarships will address a very real need to ensure more STEM talent persists to degree completion."

Sarah Hartnett, Director of Development, University of Limerick Foundation said: “Our sincere thanks to ICON for so generously supporting UL’s Access students. This wonderful scholarship programme will have a huge impact in both encouraging the next generation of scientists and engineers and, most importantly, offering financial support to those who need it most.”

Joe Quinsey, CEO, DCU Education Trust said: “STEM is at the centre of a technological revolution that is transforming the way we live and work. As we face an unscripted future, we know that a strong and diverse pipeline of talented STEM graduates will play a key role in driving innovation and addressing societal challenges. We are hugely grateful to ICON for funding Access scholarships that will enable students from socio-economically disadvantaged backgrounds to pursue STEM degrees at DCU. This support will help our students to cope with the additional costs of attending university, and ultimately, to achieve a qualification that will leave them well placed to exploit the opportunities of the future.”

Dr. Lisa Keane, Acting Director, Trinity Access, Trinity College Dublin said: “In Trinity Access we work to create pathways for students from underrepresented groups into higher professional careers. The ICON Scholar programme is an exemplar in this regard. It will directly impact the lives of our students, enabling them to engage more fully in all aspects of university life and it will also have a positive knock-on effect on their communities and on the sector as a whole.”

ICON’s scholarship programme will support students commencing with the 2022/2023 academic year.
phone +353 1 291 2883
email info-clinical@iconplc.com
web www.iconplc.com
email ICON plc, Headquarters, South County Business Park, Leopardstown, Dublin 18, Ireland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

ACG: “The global pharmaceutical solutions company on a mission to help manufacturers keep their supply chains moving”


More info >>


White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement